In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 341-350

  Kamburova, E G ^a   Koenen, H J P M ^a   Boon, L ^b   Hilbrands, L B ^a   Joosten, I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOCEROS   (Netherlands)

Author keywords

B cell; rituximab; T cell activation; Th1 Th2; transplantation

Indexed keywords

CD27 ANTIGEN; INTERLEUKIN 21; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL DIVISION; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; PHENOTYPE;

EID: 84856431756     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03833.x     Document Type: Article

References (39)

1. Smith MR,. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
2. Glennie MJ, French RR, Cragg MS, Taylor RP,. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-3837. (Pubitemid 47332625)
3. Chow KU, Sommerlad WD, Boehrer S, et al,. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43. (Pubitemid 34101111)
4. Voso MT, Pantel G, Rutella S, et al,. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 918-925.
5. Pescovitz MD,. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6 (Pt 1): 859-866. (Pubitemid 44356635)
6. Anolik JH, Barnard J, Cappione A, et al,. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590. (Pubitemid 39488683)
7. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620. (Pubitemid 43228639)
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al,. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-2152.
9. Piccio L, Naismith RT, Trinkaus K, et al,. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-714.
10. Sanz I, Anolik JH, Looney RJ,. B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12: 2546-2567.
11. Vo AA, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
12. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I,. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148. (Pubitemid 40095139)
13. Faguer S, Kamar N, Guilbeaud-Frugier C, et al,. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280. (Pubitemid 46743692)
14. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS,. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248-2252. (Pubitemid 41648473)
15. Becker YT, Becker BN, Pirsch JD, Sollinger HW,. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001. (Pubitemid 38745599)
16. Steinmetz OM, Lange-Husken F, Turner JE, et al,. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842-850. (Pubitemid 351338944)
17. Duddy ME, Alter A, Bar-Or A,. Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 2004; 172: 3422-3427. (Pubitemid 38337921)
18. Harris DP, Haynes L, Sayles PC, et al,. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-482.
19. Janeway CA Jr,., Ron J, Katz ME,. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987; 138: 1051-1055. (Pubitemid 17017883)
20. Vinuesa CG, Tangye SG, Moser B, Mackay CR,. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 853-865. (Pubitemid 41581667)
21. Avery DT, Ellyard JI, Mackay F, Corcoran LM, Hodgkin PD, Tangye SG,. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 2005; 174: 4034-4042. (Pubitemid 40395979)
22. Maarof G, Bouchet-Delbos L, Gary-Gouy H, Durand-Gasselin I, Krzysiek R, Dalloul A,. Interleukin-24 inhibits the plasma cell differentiation program in human germinal center B cells. Blood 2010; 115: 1718-1726.
23. Agematsu K, Nagumo H, Yang FC, et al,. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997; 27: 2073-2079. (Pubitemid 27346026)
24. Iwata Y, Matsushita T, Horikawa M, et al,. Characterization of a rare IL-10-competent B-cell subset in man that parallels mouse regulatory B10 cells. Blood 2010; 117: 530-541.
25. Blair PA, Norena LY, Flores-Borja F, et al,. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
26. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G,. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428. (Pubitemid 44359429)
27. Gong Q, Ou Q, Ye S, et al,. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826. (Pubitemid 40094277)
28. Thaunat O, Patey N, Gautreau C, et al,. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85: 1648-1653.
29. Tyden G, Genberg H, Tollemar J, et al,. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
30. Vos K, Thurlings RM, Wijbrandts CA, van SD, Gerlag DM, Tak PP,. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-778. (Pubitemid 46399424)
31. Deans JP, Li H, Polyak MJ,. CD20-mediated apoptosis: Signalling through lipid rafts. Immunology 2002; 107: 176-182. (Pubitemid 35279043)
32. Kheirallah S, Caron P, Gross E, et al,. Rituximab inhibits B-cell receptor signaling. Blood 2010; 115: 985-994.
33. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP,. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407. (Pubitemid 46096333)
34. Franke A, Niederfellner GJ, Klein C, Burtscher H,. Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. PLoS One 2011; 6: e16596.
35. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D,. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006; 176: 3498-3506. (Pubitemid 43363997)
36. Clatworthy MR, Watson CJ, Plotnek G, et al,. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
37. Tay SS, Plain KM, Bishop GA,. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 16-22.
38. Le TL, Thebault P, Lavault A, et al,. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11: 429-438.
39. Pallier A, Hillion S, Danger R, et al,. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-513.